Featured Research

from universities, journals, and other organizations

Synthetic Estrogens Could Lessen Risks Associated With Hormone Replacement Therapy, Study Suggests

Date:
February 6, 2008
Source:
University of Southern California
Summary:
A new class of synthetic estrogens could offer women most of the benefit and less of the risk of standard hormone replacement therapy, a study in animals suggests. Mice with induced Alzheimer's-like symptoms got better when given the synthetic hormone propylpyrazole triol (PPT). "It improved behavior much the way that estrogen does," said one of the researchers. But unlike estrogen, which enlarges the uterus and is a known risk factor for endometrial and breast cancer, PPT caused no obvious changes to the animals' reproductive tract.

A new class of synthetic estrogens could offer women most of the benefit and less of the risk of standard hormone replacement therapy, a study in animals suggests.

The study, appearing online Jan. 31 in the journal Endocrinology, reports that mice with induced Alzheimer’s-like symptoms got better when given the synthetic hormone propylpyrazole triol (PPT).

“It improved behavior much the way that estrogen does,” said study leader Christian Pike, associate professor at the USC Davis School of Gerontology.

But unlike estrogen, which enlarges the uterus and is a known risk factor for endometrial and breast cancer, PPT caused no obvious changes to the animals’ reproductive tract.

Pike called the study a first step in the search for safer compounds that mimic estrogen’s positive effects on mental function and bone density. “If hormone therapy as it is now is a problem, what are the alternatives?” he asked.

PPT is one in a class of alternatives known as selective estrogen receptor modulators, or SERMs. These are tissue-specific compounds, acting only on certain parts of the body.

Some already are commercially available. The cancer drug tamoxifen blocks estrogen in breast tissue. Another drug, raloxifene, is an estrogen-like compound that promotes bone density but inhibits estrogen action in breast and uterus.

Raloxifene has been shown to reduce the risk of cognitive impairment in postmenopausal women, Pike said. The Endocrinology study should encourage further animal and human research on the potential benefits of SERMs, he added.

Another SERM in Pike’s study, diarylpropionitrile (DPN), showed limited benefits for mice with Alzheimer’s symptoms. PPT and DPN act on different parts of the estrogen system, Pike said.

The finding of differential effects among SERMs suggests it may be possible to design an optimal compound with the best possible risk-to-reward profile.

The study was funded by the National Institute on Aging under a large grant to USC researcher Roberta Diaz Brinton, who is leading a university-wide effort to study the effects of hormone therapy on women’s health.

Doctors prescribe hormone therapy to counter some of the harmful consequences of menopause, such as losses in bone density. But other large studies have shown that hormone therapy also increases the risk of breast cancer.

USC graduate student Jenna Carroll was the other author of the study.


Story Source:

The above story is based on materials provided by University of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University of Southern California. "Synthetic Estrogens Could Lessen Risks Associated With Hormone Replacement Therapy, Study Suggests." ScienceDaily. ScienceDaily, 6 February 2008. <www.sciencedaily.com/releases/2008/02/080204221922.htm>.
University of Southern California. (2008, February 6). Synthetic Estrogens Could Lessen Risks Associated With Hormone Replacement Therapy, Study Suggests. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2008/02/080204221922.htm
University of Southern California. "Synthetic Estrogens Could Lessen Risks Associated With Hormone Replacement Therapy, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/02/080204221922.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins